Description
Diaglizid MR (Gliclazide) Tablets with Prolonged Release 30 mg. №60
Composition
Active ingredient: Gliclazide 30 mg.
Other ingredients: [List other ingredients here]
Mechanism of Action
Gliclazide, the active ingredient in Diaglizid MR tablets, is a sulfonylurea that works by stimulating insulin release from pancreatic beta cells, thereby lowering blood glucose levels.
Pharmacological Properties
Diaglizid MR tablets with prolonged release contain gliclazide, which has hypoglycemic properties and helps in regulating blood sugar levels in patients with type 2 diabetes mellitus.
Indications for Use
Diaglizid MR tablets are indicated for the treatment of type 2 diabetes mellitus to improve glycemic control by lowering blood glucose levels.
Contraindications
Do not use Diaglizid MR tablets if:
- You are allergic to gliclazide or any other ingredients in the product.
- You have type 1 diabetes.
- You have diabetic ketoacidosis.
Side Effects
Common side effects of Diaglizid MR tablets may include hypoglycemia, gastrointestinal disturbances, and skin reactions. Consult your healthcare provider if you experience any adverse effects.
Usage Instructions
Dosage: Take 1 tablet daily with a meal or as directed by a healthcare professional. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.
Benefits Compared to Analogues
Diaglizid MR tablets have shown a lower risk of hypoglycemia and cardiovascular events compared to other sulfonylureas, as demonstrated in clinical studies.
Suitable Patient Groups
Diaglizid MR tablets are suitable for adult patients with type 2 diabetes mellitus. Dosage adjustments may be necessary for elderly patients or those with renal impairment. Consult a healthcare provider for personalized recommendations.
Storage and Shelf Life
Store Diaglizid MR tablets in a cool, dry place away from direct sunlight. Keep the product out of reach of children. Check the expiration date on the packaging and do not use the tablets beyond the stated shelf life.
Packaging Description
Diaglizid MR tablets are available in a package containing 60 tablets of 30 mg each. The packaging is designed to maintain the integrity and stability of the tablets until the expiration date.
Clinical Evidence and Proven Effectiveness
Diaglizid MR (Gliclazide) tablets have been extensively studied in clinical trials. Research published in the Journal of Diabetes Investigation demonstrated the efficacy of gliclazide in reducing HbA1c levels and improving insulin sensitivity in patients with type 2 diabetes.
Furthermore, a meta-analysis published in the Journal of Clinical Pharmacy and Therapeutics compared the effectiveness of gliclazide with other sulfonylureas and found that gliclazide had a lower risk of hypoglycemia and cardiovascular events.
